New Classifications of Five Distinct “Sleep” Profi... ...
A Professional Overview of Hypertension ...
High-speed imaging tracks live brain cell activity...
Drug candidate slows motor neuron disease progress...
Drug candidate slows motor neuron disease progress...
Mark Cuban: A Master Disrupter for American Health...
Superbugs on your plate: How antimicrobial resistance spread...
June 13,2026
Can marijuana cause lung cancer?...
June 12,2026
Standard depression screening could be missing key symptoms ...
June 11,2026
More women are having babies later in life. How to improve y...
June 10,2026
For severe babesiosis, red blood cell exchange is associated...
June 09,2026
Cause or effect? Study answers question about gene linked wi...
June 08,2026
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
Eye Infections (Updated) | Clinical Medicine...
Announcement of the 2025 Nobel Prize in ...
Dr. Fauci among hundreds who've contract...
Why are young, healthy adults experienci...
Reprogramming Stem Cells Could Cure Type...
More News
Ruxolitinib Improves Spleen Volume, TSS in Myelofibrosis Irrespective of Anemia, Transfusion Status

Ruxolitinib Improves Spleen Volume, TSS in Myelofibrosis Irrespective of Anemia, Transfusion Status

Ruxolitinib (Jakafi) was found to improve spleen volume and tumor symptom score (TSS) in patients with myelofibrosis, irrespective of their anemia and transfusion status, according to data from a post
World medicine November 09,2023
Ruxolitinib Improves Spleen Volume, TSS in Myelofibrosis Irrespective of Anemia, Transfusion Status

Ruxolitinib Improves Spleen Volume, TSS in Myelofibrosis Irrespective of Anemia, Transfusion Status

Ruxolitinib (Jakafi) was found to improve spleen volume and tumor symptom score (TSS) in patients with myelofibrosis, irrespective of their anemia and transfusion status, according to data from a post
World medicine November 09,2023
Cracking the code: recent discoveries transform our understanding of cancer-immunity cycle

Cracking the code: recent discoveries transform our understanding of cancer-immunity cycle

In a recent review published inImmunity, researchers reviewed tumor-immunity cycle data.Study:The cancer-immunity cycle: Indication, genotype, and immunotype. Image Credit:Alpha Taur
World medicine November 09,2023
Cracking the code: recent discoveries transform our understanding of cancer-immunity cycle

Cracking the code: recent discoveries transform our understanding of cancer-immunity cycle

In a recent review published inImmunity, researchers reviewed tumor-immunity cycle data.Study:The cancer-immunity cycle: Indication, genotype, and immunotype. Image Credit:Alpha Taur
World medicine November 09,2023
Are migraines linked to gut health and chronic non-communicable diseases?

Are migraines linked to gut health and chronic non-communicable diseases?

In a recent review published inNutrients, researchers examine the Links Between Migraines, Gut Health, and Chronic Non-Communicable Diseases (CNCDs).Study:Linking Migraine to Gut Dysbiosis
World medicine November 09,2023
Are migraines linked to gut health and chronic non-communicable diseases?

Are migraines linked to gut health and chronic non-communicable diseases?

In a recent review published inNutrients, researchers examine the Links Between Migraines, Gut Health, and Chronic Non-Communicable Diseases (CNCDs).Study:Linking Migraine to Gut Dysbiosis
World medicine November 09,2023
UTHealth Houston clinical trial therapy shrinks tumor of pancreatic cancer patient

UTHealth Houston clinical trial therapy shrinks tumor of pancreatic cancer patient

Demetrios Stroubakis, 55, thought he was having a gallbladder attack when he arrived at the emergency room in August 2021 with jaundice. Instead, he was shocked to be diagnosed with pancreatic cancer.
World medicine November 09,2023
UTHealth Houston clinical trial therapy shrinks tumor of pancreatic cancer patient

UTHealth Houston clinical trial therapy shrinks tumor of pancreatic cancer patient

Demetrios Stroubakis, 55, thought he was having a gallbladder attack when he arrived at the emergency room in August 2021 with jaundice. Instead, he was shocked to be diagnosed with pancreatic cancer.
World medicine November 09,2023
Tumor debulking does not impact quality of life in metastatic colorectal cancer, study finds

Tumor debulking does not impact quality of life in metastatic colorectal cancer, study finds

New research in the October 2023 issue ofJNCCN-;Journal of the National Comprehensive Cancer Networkfinds that intensive local-regional treatment to remove as much tumor as possible (known
World medicine November 09,2023
Tumor debulking does not impact quality of life in metastatic colorectal cancer, study finds

Tumor debulking does not impact quality of life in metastatic colorectal cancer, study finds

New research in the October 2023 issue ofJNCCN-;Journal of the National Comprehensive Cancer Networkfinds that intensive local-regional treatment to remove as much tumor as possible (known
World medicine November 09,2023
Hackensack University Medical Center establishes new Center for Weight Loss and Metabolic Health

Hackensack University Medical Center establishes new Center for Weight Loss and Metabolic Health

Hackensack University Medical Center has established the Center for Weight Loss and Metabolic Health, an integrated program to help people who have struggled to lose weight to achieve and maintain the
World medicine November 09,2023
Hackensack University Medical Center establishes new Center for Weight Loss and Metabolic Health

Hackensack University Medical Center establishes new Center for Weight Loss and Metabolic Health

Hackensack University Medical Center has established the Center for Weight Loss and Metabolic Health, an integrated program to help people who have struggled to lose weight to achieve and maintain the
World medicine November 09,2023
Rusfertide Offers Durable Hematocrit Control in Phlebotomy-Dependent Polycythemia Vera

Rusfertide Offers Durable Hematocrit Control in Phlebotomy-Dependent Polycythemia Vera

Rusfertide (PTG-300) demonstrated freedom from phlebotomy, sustained hematocrit control, and 12-week treatment completion in 69.2% (n = 18/26) vs 18.5% (n = 5/27) of patients with phlebotomy-dependent
World medicine November 09,2023
Rusfertide Offers Durable Hematocrit Control in Phlebotomy-Dependent Polycythemia Vera

Rusfertide Offers Durable Hematocrit Control in Phlebotomy-Dependent Polycythemia Vera

Rusfertide (PTG-300) demonstrated freedom from phlebotomy, sustained hematocrit control, and 12-week treatment completion in 69.2% (n = 18/26) vs 18.5% (n = 5/27) of patients with phlebotomy-dependent
World medicine November 09,2023
Study sheds new light on the relationship between autism traits and mental health in middle childhood

Study sheds new light on the relationship between autism traits and mental health in middle childhood

A long-term study by UC Davis Health researchers sheds new light on the relationship between autism traits and mental health in middle childhood. The paper, published in the journalAutism, finds
World medicine November 09,2023
Study sheds new light on the relationship between autism traits and mental health in middle childhood

Study sheds new light on the relationship between autism traits and mental health in middle childhood

A long-term study by UC Davis Health researchers sheds new light on the relationship between autism traits and mental health in middle childhood. The paper, published in the journalAutism, finds
World medicine November 09,2023
NOX-A12 Plus Bevacizumab and Radiotherapy Shows Sustained Survival in Glioblastoma

NOX-A12 Plus Bevacizumab and Radiotherapy Shows Sustained Survival in Glioblastoma

The addition of the CXCL12 inhibitor NOX-A12 (olaptesed pegol) to standard frontline therapy with radiation and bevacizumab (Avastin) led to an overall survival (OS) rate of 83% (n = 5/6) at a median
World medicine November 09,2023
NOX-A12 Plus Bevacizumab and Radiotherapy Shows Sustained Survival in Glioblastoma

NOX-A12 Plus Bevacizumab and Radiotherapy Shows Sustained Survival in Glioblastoma

The addition of the CXCL12 inhibitor NOX-A12 (olaptesed pegol) to standard frontline therapy with radiation and bevacizumab (Avastin) led to an overall survival (OS) rate of 83% (n = 5/6) at a median
World medicine November 09,2023
Liso-Cel Elicits ORR of 97% in Relapsed/Refractory Follicular Lymphoma

Liso-Cel Elicits ORR of 97% in Relapsed/Refractory Follicular Lymphoma

A single administration of lisocabtagene maraleucel (Breyanzi; liso-cel) provided deep and durable remissions when used as third-line treatment in patients with relapsed or refractory follicular lymph
World medicine November 09,2023
Liso-Cel Elicits ORR of 97% in Relapsed/Refractory Follicular Lymphoma

Liso-Cel Elicits ORR of 97% in Relapsed/Refractory Follicular Lymphoma

A single administration of lisocabtagene maraleucel (Breyanzi; liso-cel) provided deep and durable remissions when used as third-line treatment in patients with relapsed or refractory follicular lymph
World medicine November 09,2023
More News
Week’s Top
Podcasts
... Preparing for a tough exam? A tough gym workout could help with your studies ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... Brain activity goes to extremes in soccer fans, neuroimaging reveals ...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com